ALIMERA SCIENCES, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-06: Form 8-K; Period of report 2018-12-04; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2018-11-29: Form 8-K; Period of report 2018-11-28; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
- 2018-11-06: Form 8-K; Period of report 2018-11-05; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2018-09-05: Form 8-K; Period of report 2018-09-05; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-06 | 8-K | 2018-12-04 | 7.01 Regulation FD Disclosure | 7.01 On December 4, 2018, C. Daniel Myers, Chief Executive Officer of Alimera Sciences, Inc. (the “Company” or “Alimera”), stated during his presentation on behalf of the Company at the 11th Annual LD Micro Main Event in Los Angeles, California that the Company believes it will likely finish 2018 with annual revenue of close to $45 million. | alim8k.htm |
| 2018-11-29 | 8-K | 2018-11-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On November 28, 2018, the Board of Directors (the “Board”) of Alimera Sciences, Inc. (the “Company”) approved a succession plan (the “Succession Plan”) that will generally take effect on January 2, 2019 (the “Transition Date”). 7.01 On November 29, 2018, the Company issued a press release announcing the Succession Plan. | alim8k.htm |
| 2018-11-06 | 8-K | 2018-11-05 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 5, 2018, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the third quarter ended September 30, 2018. 7.01 The earnings webcast will include certain non-GAAP financial measures. | alim8k.htm |
| 2018-09-05 | 8-K | 2018-09-05 | 7.01 Regulation FD Disclosure | 7.01 On September 5, 2018, at 8:30 a.m. | alim8k.htm |
| 2018-09-05 | 8-K | 2018-08-31 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 related to the Exchange Agreement and below in Item 5.03 related to the Series C Preferred Stock is hereby incorporated by reference into this Item 3.02. 3.03 The information contained above in Item 1.01 related to the Exchange Agreement and below in Item 5.03 related to the Series C Preferred Stock is hereby incorporated by reference into this Item 3.03. 5.03 On September 4, 2018, as a condition to closing of the Exchange Agreement, the Company filed with the Secretary of State of the State Delaware (the “Delaware Secretary of State”) a Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock (the “Series C Certificate of Designation”). 5.07 The Company’s Certificate of Designation of Series A Convertible Preferred Stock provides, among other things, that the Company will not, without first obtaining the affirmative vote or written consent of the holders of at least 70% of the then-outstanding shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”), voting together as a separate class, redeem, purchase or otherwise acquire any shares of Preferred Stock (subject to certain exceptions that do not apply in this instance). | alim8k.htm |
| 2018-08-01 | 8-K | 2018-07-30 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 Alimera Sciences, Inc. (“we,” “our,” or “us”) received notice in June 2018 from The Nasdaq Stock Market (“Nasdaq”) that we failed to comply with the Nasdaq Global Market’s minimum bid requirement because our stock price was below $1.00 per common share for 30 consecutive business days. | alim8k.htm |
| 2018-07-30 | 8-K | 2018-07-30 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On July 30, 2018, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the second quarter ended June 30, 2018. 7.01 The earnings webcast will include certain non-GAAP financial measures. | alim8k.htm |
| 2018-06-22 | 8-K | 2018-06-19 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.07 Submission of Matters to a Vote of Security Holders | 3.01 On June 21, 2018, Alimera Sciences, Inc. (the “Company”) received notice from The Nasdaq Stock Market (“Nasdaq”) that as of June 20, 2018, the closing bid price for the Company’s common stock on the Nasdaq Global Market was below $1.00 for the last 30 consecutive business days and that the Company is therefore not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). 5.07 Proposal 1: The election of one director to serve as a Class II director for a term of three years until the 2021 annual meeting of stockholders. | alim8k.htm |
| 2018-06-21 | 8-K | 2018-06-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On June 21, 2018, Alimera Sciences, Inc. (the “Company”) issued a press release announcing that, based upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors (the “Board”), on June 19, 2018 the Board appointed Mary T. Szela to the Board as a Class II Director, with a term expiring at the Company’s 2021 annual meeting of stockholders. | alim8k.htm |
| 2018-06-04 | 8-K | 2018-06-01 | 1.02 Termination of a Material Definitive Agreement | 1.02 On October 20, 2017, Alimera Sciences, Inc. (the “Company”) entered into a Common Stock Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”). | alim8-k.htm |
| 2018-05-03 | 8-K | 2018-05-02 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 2, 2018, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the first quarter ended March 31, 2018. 7.01 The earnings webcast will include certain non-GAAP financial measures. | alim8k.htm |
| 2018-03-09 | 8-K | 2018-03-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On March 7, 2018, Glen Bradley, Ph.D. notified the Board of Directors (the “Board”) of Alimera Sciences, Inc. (the “Company”) that he did not intend to stand for re-election at the Company’s 2018 Annual Meeting of Stockholders. | alim8k.htm |
| 2018-02-28 | 8-K | 2018-02-28 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On February 28, 2018, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the fourth quarter and full year ended December 31, 2017. 7.01 The earnings webcast will include certain non-GAAP financial measures. | alim8k.htm |
| 2018-01-08 | 8-K | 2018-01-05 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Definitive Material Agreement. 2.03 The information disclosed in Item 1.01 above is incorporated herein by reference. | alim8-k.htm |